181 related articles for article (PubMed ID: 33616086)
21. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
[TBL] [Abstract][Full Text] [Related]
22. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
[TBL] [Abstract][Full Text] [Related]
23. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses.
Desai DD; Harbers SO; Flores M; Colonna L; Downie MP; Bergtold A; Jung S; Clynes R
J Immunol; 2007 May; 178(10):6217-26. PubMed ID: 17475849
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
25. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of the response of naive and memory CD8 T cells to antigen: similarities and differences.
Zimmermann C; Prévost-Blondel A; Blaser C; Pircher H
Eur J Immunol; 1999 Jan; 29(1):284-90. PubMed ID: 9933110
[TBL] [Abstract][Full Text] [Related]
28. Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.
Bellavance EC; Kohlhapp FJ; Zloza A; O'Sullivan JA; McCracken J; Jagoda MC; Lacek AT; Posner MC; Guevara-Patino JA
J Immunol; 2011 Mar; 186(6):3309-16. PubMed ID: 21289306
[TBL] [Abstract][Full Text] [Related]
29. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
30. Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.
Hong C; Lee H; Park YK; Shin J; Jung S; Kim H; Hong S; Park SH
Cancer Res; 2009 May; 69(10):4301-8. PubMed ID: 19401453
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
32. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
33. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.
Yamauchi T; Hoki T; Oba T; Saito H; Attwood K; Sabel MS; Chang AE; Odunsi K; Ito F
JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32255766
[TBL] [Abstract][Full Text] [Related]
34. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.
Singh V; Ji Q; Feigenbaum L; Leighty RM; Hurwitz AA
J Immunother; 2009; 32(2):129-39. PubMed ID: 19238011
[TBL] [Abstract][Full Text] [Related]
35. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
36. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
Elife; 2020 Mar; 9():. PubMed ID: 32122464
[TBL] [Abstract][Full Text] [Related]
37. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.
Pollizzi KN; Patel CH; Sun IH; Oh MH; Waickman AT; Wen J; Delgoffe GM; Powell JD
J Clin Invest; 2015 May; 125(5):2090-108. PubMed ID: 25893604
[TBL] [Abstract][Full Text] [Related]
38. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
39. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
40. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
Binder DC; Engels B; Arina A; Yu P; Slauch JM; Fu YX; Karrison T; Burnette B; Idel C; Zhao M; Hoffman RM; Munn DH; Rowley DA; Schreiber H
Cancer Immunol Res; 2013 Aug; 1(2):123-33. PubMed ID: 24455752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]